| Literature DB >> 33850735 |
Lian-Zhong Wu1,2, Yi-Qin Weng1,2, Yi-Xin Ling1,2, Shu-Juan Zhou1, Xiao-Kai Ding3, Si-Qi Wu2, Kang Yu1, Song-Fu Jiang1, Yi Chen1.
Abstract
BACKGROUND: The mammalian target of rapamycin (mTOR) signaling pathway is vital for the regulation of cell metabolism, growth and proliferation in the kidney. This study aims to show current research focuses and predict future trends about mTOR pathway in kidney disease by the methods of scientometric analysis.Entities:
Keywords: Bibliometrics; CiteSpace; TOR serine-threonine kinases; VOSviewer; kidney diseases
Year: 2021 PMID: 33850735 PMCID: PMC8039620 DOI: 10.21037/tau-20-1469
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Figure 1Scientometric analysis of mTOR signaling pathway in kidney disease revealed in the flow diagram. K, scale factor; Z, z-sore, standard score of the quantity of appearances of keywords. mTOR, mammalian target of rapamycin.
Figure 2Countries/regions involved in mTOR signaling pathway in kidney disease research. (A) Number and percentage of publications. (B) The top 15 countries/regions with the largest publications. (C) Heat map of publications in countries/regions. (D) Average citations per paper and total citation number of top 15 countries/regions with the largest production. (E) The number of articles in 70 countries/regions. (F) The number of manuscripts in different institutions. (G) Publication number and citation per paper of top 20 most productive institutions. (H) Collaboration between institutions. mTOR, mammalian target of rapamycin.
The top 15 institutes ranked by the citation number of articles about mTOR signaling pathway in kidney disease
| Rank | Institution | Country/region | Citations | Publications | Average citation per paper |
|---|---|---|---|---|---|
| 1 | Harvard Univ | USA | 3,244 | 52 | 62.38 |
| 2 | NCI | USA | 1,803 | 35 | 51.51 |
| 3 | Univ Freiburg | Germany | 1,704 | 25 | 68.16 |
| 4 | Univ Michigan | USA | 1,675 | 28 | 59.82 |
| 5 | Med Univ Vienna | Austria | 1,617 | 21 | 77.00 |
| 6 | Univ Zurich Hosp | Switzerland | 1,523 | 28 | 54.39 |
| 7 | Cleveland Clin | USA | 1,464 | 26 | 56.31 |
| 8 | Univ Paris 05 | France | 1,447 | 36 | 40.19 |
| 9 | Mayo Clin | USA | 1,428 | 31 | 46.06 |
| 10 | Charite | Germany | 1,367 | 29 | 47.14 |
| 11 | Inst Gustave Roussy | France | 1,276 | 13 | 98.15 |
| 12 | Mem Sloan Kettering Canc Ctr | USA | 1,258 | 34 | 37.00 |
| 13 | Brigham & Womens Hosp | USA | 1,194 | 39 | 30.62 |
| 14 | Hop Necker Enfants Malad | France | 1,109 | 24 | 46.21 |
| 15 | Hannover Med Schm | Germany | 1,073 | 51 | 21.04 |
TOR, mammalian target of rapamycin.
Figure 3Citation networks and collaboration among organizations and authors. (A) The top 100 highly cited journals with network visualization. (B) The top 100 highly cited journals with citation network. (C) The co-authorship among top 70 highly cited authors. (D) The top 70 highly cited authors with network visualization. (E) The top 20 strongest citation bursts of references. (F) A co-citation network of references.
The top 20 journals contributed to mTOR signaling pathway in kidney disease ranked by citation number
| Rank | Journal name | Country/region | Citations | Documents | Average citation | Journal impact factor of 2019 |
|---|---|---|---|---|---|---|
| 1 |
| USA | 2,882 | 48 | 60.04 | 9.274 |
| 2 |
| USA | 2,267 | 96 | 23.61 | 4.264 |
| 3 |
| USA | 2,181 | 17 | 128.29 | 9.412 |
| 4 |
| USA | 1,842 | 31 | 59.42 | 4.238 |
| 5 |
| USA | 1,737 | 80 | 21.71 | 7.338 |
| 6 |
| USA | 1,597 | 61 | 26.18 | 3.144 |
| 7 |
| USA | 1,514 | 48 | 31.54 | 8.945 |
| 8 |
| USA | 1,455 | 67 | 21.72 | 2.740 |
| 9 |
| USA | 1,452 | 15 | 96.80 | 9.727 |
| 10 |
| England | 1,349 | 51 | 26.45 | 4.531 |
| 11 |
| England | 1,273 | 22 | 57.86 | 5.100 |
| 12 |
| England | 1,068 | 68 | 15.71 | 3.177 |
| 13 |
| USA | 1,038 | 14 | 74.14 | 11.864 |
| 14 |
| England | 952 | 7 | 136.00 | 36.130 |
| 15 |
| England | 940 | 9 | 104.44 | 74.699 |
| 16 |
| England | 855 | 6 | 142.50 | 4.097 |
| 17 |
| USA | 820 | 98 | 8.37 | 0.784 |
| 18 |
| England | 570 | 14 | 40.71 | 20.711 |
| 19 |
| USA | 560 | 14 | 40.00 | 4.966 |
| 20 |
| England | 489 | 15 | 32.60 | 3.262 |
Figure 4The visualization of keywords and MeSH terms. (A) The keywords analysis for the mTOR signaling pathway in kidney disease. (B) The clustering analysis of co-citation network for the mTOR signaling pathway in kidney disease. (C) The network visualization of keywords. (D) Heat map of keywords.
Figure 5Time zone view of cluster nodes and timeline visualization of keywords and MeSH terms. (A) The visualization of term timeline from 1986 to 2020. (B) The visualization of keywords timeline from 1986 to 2020. (C) The visualization of time zone view of cluster nodes. (D) Dual-map overlays of publications about mTOR in kidney disease.